Abstract
Bio-Techne will acquire Exosome Diagnostics for $250 million, plus up to $325 million in potential milestone payments. Waltham, Mass.-based Exosome currently offers a urine test to detect RNA contained in vesicles called exosomes released by prostate cancer cells. The company is also developing several tests to diagnose other cancers from exosomes released by other cells into the blood. Bio-Techne says this is its 14th acquisition in five years and its “most promising to date.”
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
